A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients With Refractory Hematologic Malignancies

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-06-0511
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)